© 2021 MJH Life Sciences and Neurology Live. All rights reserved.
© 2021 MJH Life Sciences™ and Neurology Live. All rights reserved.
Michael Panzara, MD, MPH, chief medical officer, and head, therapeutics discovery and development, Wave Life Sciences
August 25, 2021
The chief medical officer of Wave Life Sciences outlined the FOCUS-C9 study, which has incorporated feedback from patients with both ALS and FTD, as well as investigators in the research field.
August 23, 2021
The potential of a new investigational treatment for C9orf72-associated amyotrophic lateral sclerosis and frontotemporal could offer long-lasting effects for patients.
August 20, 2021
The chief medical officer of Wave Life Sciences spoke on the FOCUS-C9 study and the potential of WVE-004 to generate positive outcomes for patients.
August 19, 2021
The potential of a new investigational treatment, WVE-004, was discussed by the chief medical officer of Wave Life Sciences, the company that developed the molecule for C9-ALS and C9-FTD.